Amgen Beats First Quarter Estimates; Will Study Apremilast (Otezla) in COVID-19 Patients

Reuters  |

Image source: Amgen

By Deena Beasley

(Reuters) - Amgen Inc on Thursday reported better-than-expected first-quarter results on Thursday and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.

Otezla, which Amgen acquired last year from

Celgene Corp as part of Celgene’s buyout by Bristol Myers Squibb Co, is a pill that helps reduce overactive inflammation. Other similar medicines are also being tested to see if they can help COVID-19 patients.

Amgen, which maintained its full-year earnings forecast, also said it is working with partner Adaptive Biotechnologies Corp

Betting Against Elon Musk Has Not Been Profitable

to identify antibodies targeting the novel coronavirus that may be developed into a drug to potentially prevent or treat COVID-19.

Amgen said strong first-quarter sales of Otezla, along with higher volume sales of drugs like cholesterol treatment Repatha, contributed to an 11% increase in revenue for the period.

The company last year launched a lower-priced Repatha option aimed at reducing out-of-pocket costs for Medicare patients.

The biotechnology company reported an adjusted profit of $4.17 per share, up 17% from a year earlier and well above analysts’ average expectations of $3.76, according to Refinitiv IBES.

Amgen said the results were driven by revenue of $6.16 billion and fewer shares outstanding. That topped Wall Street estimates for revenue of just under $6 billion.

Net profit fell 3% to $3.07 per share due to higher operating costs that were partially offset by the lower share count.

For 2020, the Thousand Oaks, California-based company said it still expects adjusted earnings of $14.85 to $15.60 per share on revenue of $25 billion to $25.6 billion.

Reporting By Deena Beasley; Editing by Bill Berkrot.

_____

Source: Reuters

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement

Market Movers

Sponsored Financial Content